MCID: ESN004
MIFTS: 42

Eosinophilic Gastritis

Categories: Gastrointestinal diseases

Aliases & Classifications for Eosinophilic Gastritis

MalaCards integrated aliases for Eosinophilic Gastritis:

Name: Eosinophilic Gastritis 12 15 73
Eosinophilic Enteropathy 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4030
ICD9CM 35 535.7
MeSH 44 C535952
NCIt 50 C27052
SNOMED-CT 68 66329006

Summaries for Eosinophilic Gastritis

MalaCards based summary : Eosinophilic Gastritis, also known as eosinophilic enteropathy, is related to eosinophilic gastroenteritis and gastroenteritis. An important gene associated with Eosinophilic Gastritis is IL5 (Interleukin 5), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include skin and b cells, and related phenotypes are digestive/alimentary and hematopoietic system

Related Diseases for Eosinophilic Gastritis

Diseases related to Eosinophilic Gastritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 176)
# Related Disease Score Top Affiliating Genes
1 eosinophilic gastroenteritis 31.9 CCL11 IL3 IL5
2 gastroenteritis 30.2 CCL11 IL4 IL5
3 hypereosinophilic syndrome 29.5 CCL11 IL13 IL3 IL4 IL5
4 eosinophilic enteropathy 11.4
5 gastritis 10.7
6 fungal esophagitis 10.3 ATP12A ATP4A
7 diclofenac allergy 10.3 ATP12A ATP4A
8 pemphigoid gestationis 10.3 CCL11 IL5
9 gastroduodenal crohn's disease 10.3 ATP12A ATP4A
10 neonatal candidiasis 10.3 ATP12A ATP4A
11 photoallergic dermatitis 10.3 ATP12A ATP4A
12 squamous papillomatosis 10.3 ATP12A ATP4A
13 cytokine deficiency 10.3 IL13 IL5
14 toxic megacolon 10.3 ATP12A ATP4A
15 aspiration pneumonitis 10.3 ATP12A ATP4A
16 gastrointestinal neuroendocrine benign tumor 10.3 ATP12A ATP4A
17 gastric antral vascular ectasia 10.3 ATP12A ATP4A
18 granulomatous gastritis 10.3 ATP12A ATP4A
19 esophageal candidiasis 10.3 ATP12A ATP4A
20 gastric neuroendocrine neoplasm 10.3 ATP12A ATP4A
21 acute laryngitis 10.3 ATP12A ATP4A
22 laryngitis 10.3 ATP12A ATP4A
23 chronic meningitis 10.3 CCL11 IL5
24 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL13 IL5
25 duodenitis 10.3 ATP12A ATP4A
26 rumination disorder 10.3 ATP12A ATP4A
27 active peptic ulcer disease 10.3 ATP12A ATP4A
28 congenital disorder of deglycosylation 10.3 ATP12A ATP4A
29 respiratory syncytial virus infectious disease 10.3 IL13 IL5
30 bladder calculus 10.3 ATP12A ATP4A
31 ischemic neuropathy 10.3 ATP12A ATP4A
32 bile reflux 10.3 ATP12A ATP4A
33 drug allergy 10.3 ATP12A IL5
34 capillary disease 10.3 ATP12A ATP4A
35 paragonimiasis 10.2 IL13 IL5
36 peptic esophagitis 10.2 ATP12A ATP4A
37 dyskinesia of esophagus 10.2 ATP12A ATP4A
38 hernia, hiatus 10.2 ATP12A ATP4A
39 anismus 10.2 ATP12A ATP4A
40 postsurgical hypothyroidism 10.2 ATP12A ATP4A
41 cough variant asthma 10.2 IL4 IL5
42 lymphocytic colitis 10.2 ATP12A ATP4A
43 esophageal atresia/tracheoesophageal fistula 10.2 ATP12A ATP4A
44 clostridium difficile colitis 10.2 ATP12A ATP4A
45 scleritis 10.2 IL4 IL5
46 diarrhea 1, secretory chloride, congenital 10.2 ATP12A ATP4A
47 egg allergy 10.2 IL4 IL5
48 microscopic colitis 10.2 ATP12A ATP4A
49 laryngeal tuberculosis 10.2 ATP12A ATP4A
50 sulfamethoxazole allergy 10.2 IL4 IL5

Graphical network of the top 20 diseases related to Eosinophilic Gastritis:



Diseases related to Eosinophilic Gastritis

Symptoms & Phenotypes for Eosinophilic Gastritis

MGI Mouse Phenotypes related to Eosinophilic Gastritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 ATP12A ATP4A FOXP3 IL13 IL18 IL33
2 hematopoietic system MP:0005397 9.85 ATP4A CCL11 CCL24 FOXP3 IL13 IL15
3 immune system MP:0005387 9.65 ATP4A CCL11 CCL24 FOXP3 IL13 IL15
4 respiratory system MP:0005388 9.17 CCL11 CCL24 FOXP3 IL13 IL33 IL4

Drugs & Therapeutics for Eosinophilic Gastritis

Drugs for Eosinophilic Gastritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
3
Alginic acid Approved, Investigational Phase 4 9005-32-7
4
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3, 138530-94-6 9578005
5
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Cromolyn Sodium Phase 4
18 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable
19 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Soy Bean Phase 4,Phase 2,Phase 3,Not Applicable
21 Olive Phase 4
22 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
25 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
26
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
27 Reslizumab Approved, Investigational Phase 3,Phase 2
28
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
29
Ketotifen Approved Phase 3 34580-14-8, 34580-13-7 3827
30
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
31 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunoglobulins Phase 3,Phase 2,Phase 1
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35 Antibodies Phase 3,Phase 2,Phase 1
36 Antipruritics Phase 3,Not Applicable
37 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Histamine H1 Antagonists Phase 3
40 Histamine Antagonists Phase 3
41
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
42
Infliximab Approved Phase 2 170277-31-3
43 tannic acid Approved Phase 2,Not Applicable
44
Benzocaine Approved, Investigational Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
45
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
46
Losartan Approved Phase 2 114798-26-4 3961
47
Bethanechol Approved Phase 2 674-38-4 2370
48
mometasone furoate Approved, Vet_approved Phase 2 83919-23-7
49 Indoleacetic Acids Phase 2
50 Antirheumatic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 137)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
3 EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
4 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Active, not recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
5 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
6 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
11 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
12 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
13 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
14 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
15 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
16 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
17 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
18 Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
19 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Active, not recruiting NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
20 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
21 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
22 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
23 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
24 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
25 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
26 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
27 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
28 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
29 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
30 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
31 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
32 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
33 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
34 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
35 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
36 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
37 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
38 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
39 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
40 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
41 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
42 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Recruiting NCT03029091 Phase 2 Losartan Potassium
43 Milk Patch for Eosinophilic Esophagitis Active, not recruiting NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
44 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Active, not recruiting NCT01821898 Phase 2 Oral Budesonide
45 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03191864 Phase 2 APT-1011;Placebo
46 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
47 An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Enrolling by invitation NCT03664960 Phase 2 AK002
48 DEGS - Dupilumab for Eosinophilic Gastritis Study Not yet recruiting NCT03678545 Phase 2 Dupilumab (blinded);Placebo (blinded);Dupilumab (open-label)
49 Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2 Florence 30 μg/mL;Florence 60 μg/mL;Florence 90 μg/mL
50 Mepo for EoE Study Not yet recruiting NCT03656380 Phase 2 Mepolizumab 300 mg;Mepolizumab 100 mg

Search NIH Clinical Center for Eosinophilic Gastritis

Cochrane evidence based reviews: eosinophilic enteropathy

Genetic Tests for Eosinophilic Gastritis

Anatomical Context for Eosinophilic Gastritis

MalaCards organs/tissues related to Eosinophilic Gastritis:

41
Skin, B Cells

Publications for Eosinophilic Gastritis

Articles related to Eosinophilic Gastritis:

(show all 44)
# Title Authors Year
1
Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment. ( 29476289 )
2018
2
Severe upper gastrointestinal bleeding due to eosinophilic gastritis. ( 30017211 )
2018
3
Eosinophilic gastritis with involvement of esophageal gastricA inlet patch. ( 29108982 )
2017
4
Gene Expression Patterns in Distinct Endoscopic Findings for Eosinophilic Gastritis in Children. ( 28526277 )
2017
5
Hypereosinophilic Syndrome With Eosinophilic Gastritis. ( 28491930 )
2017
6
Eosinophilic Enteropathy Presenting as Small Bowel Obstruction. ( 30454227 )
2017
7
Primary Eosinophilic Gastritis in a Child with Gastric Outlet Obstruction. ( 26768007 )
2016
8
Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database. ( 25988554 )
2015
9
Eosinophilic Gastritis Presenting as Tissue Necrosis. ( 26668805 )
2015
10
A man with unsuspected marine eosinophilic gastritis. ( 25467651 )
2015
11
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2A immunity, and a unique gastric transcriptome. ( 25234644 )
2014
12
Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. ( 24957155 )
2014
13
Eosinophilic gastritis with gastric outlet obstruction mimicking infantile hypertrophic pyloric stenosis. ( 25222812 )
2014
14
Rare association of IgA nephropathy with nephrotic syndrome in a patient with eosinophilic gastritis. ( 24969211 )
2014
15
A Childhood Case of Eosinophilic Gastritis and Protein-Losing Enteropathy. ( 24351503 )
2013
16
Gastric pneumatosis with associated eosinophilic gastritis in four black and white ruffed lemurs (Varecia variegata variegata). ( 23505706 )
2013
17
Snakeskin-like pattern mimicking portal hypertensive gastropathy in patient with eosinophilic gastritis. ( 22211417 )
2012
18
Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. ( 21169993 )
2011
19
Transmural eosinophilic gastritis with gastric outlet obstruction: case report and review of the literature. ( 20501003 )
2010
20
A case of eosinophilic gastritis secondary to ulcerative colitis. ( 20533119 )
2010
21
Eosinophilic gastritis masquerading as gastric carcinoma. ( 20551571 )
2010
22
Eosinophilic gastritis with idiopathic thrombocytopaenic purpura: coincidence or association? ( 19741546 )
2009
23
Collagenous colitis and eosinophilic gastritis in a 4-year old girl: a case report and review of the literature. ( 17718794 )
2007
24
Eosinophilic gastritis; an unusual and overlooked cause of chronic abdominal pain. ( 18693615 )
2007
25
Symptomatic eosinophilic gastritis cured with Helicobacter pylori eradication. ( 16284301 )
2005
26
Eosinophilic gastritis--an unusual cause of gastric outlet obstruction. ( 11400803 )
2001
27
Eosinophilic gastritis due to Anisakis: a case report. ( 10757855 )
2000
28
Cancer-like eosinophilic gastritis. ( 7956968 )
1994
29
Corticosteroid resistance in eosinophilic gastritis--relation to in vitro eosinophil survival and interleukin 5. ( 8452321 )
1993
30
Failure of ranitidine and omeprazole treatment in eosinophilic gastritis with ulceration. ( 1763563 )
1991
31
Superficial eosinophilic gastritis in laboratory beagle dogs attributable probably to diet. ( 2385038 )
1990
32
General diagnosis case of the day. Eosinophilic gastritis. ( 2718869 )
1989
33
Eosinophilic gastritis. ( 3102801 )
1987
34
Diffuse eosinophilic gastritis. ( 7097139 )
1982
35
Case report: eosinophilic gastritis simulating a neoplasm. ( 736058 )
1978
36
Scirrhous eosinophilic gastritis in dogs with gastric arteritis. ( 919234 )
1977
37
Eosinophilic gastritis. Radiologic-pathologic correlation (RPC) from the Armed Forces Institute of Pathology (AFIP). ( 935469 )
1976
38
Endoscopic diagnosis of eosinophilic gastritis. ( 4648828 )
1972
39
Eosinophilic gastritis. A case report. ( 4329046 )
1971
40
Eosinophilic gastritis: a case report and etiological investigation. ( 4099423 )
1971
41
Polypoid eosinophilic gastritis. ( 5435951 )
1970
42
Eosinophilic gastritis. ( 6071536 )
1967
43
Primary infiltrative eosinophilic gastritis, enteritis and peritonitis; clinical and pathological manifestations of hypersensitivity. ( 14366111 )
1955
44
A case of eosinophilic gastritis. ( 14895945 )
1951

Variations for Eosinophilic Gastritis

Expression for Eosinophilic Gastritis

Search GEO for disease gene expression data for Eosinophilic Gastritis.

Pathways for Eosinophilic Gastritis

Pathways related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 CCL11 CCL24 CCL26 IL13 IL15 IL18
2
Show member pathways
13.55 CCL11 CCL24 CCL26 IL13 IL15 IL18
3
Show member pathways
13.43 CCL11 CCL24 CCL26 IL13 IL15 IL18
4
Show member pathways
13.3 CCL11 CCL24 CCL26 IL13 IL15 IL18
5
Show member pathways
13.28 CCL11 IL13 IL15 IL18 IL3 IL33
6
Show member pathways
13.2 CCL11 CCL24 CCL26 IL13 IL15 IL18
7
Show member pathways
12.8 CCL11 FOXP3 IL13 IL15 IL18 IL3
8 12.76 IL13 IL15 IL3 IL4 IL5
9
Show member pathways
12.71 IL13 IL15 IL18 IL33 IL4
10
Show member pathways
12.55 FOXP3 IL13 IL18 IL4 IL5
11
Show member pathways
12.48 IL13 IL3 IL4 IL5
12
Show member pathways
12.35 IL13 IL15 IL3 IL4 IL5
13
Show member pathways
12.27 CCL11 IL13 IL4 IL5
14
Show member pathways
12.21 IL13 IL15 IL18 IL3 IL4 IL5
15 11.96 IL15 IL3 IL4 IL5
16 11.95 CCL11 IL13 IL18 IL4
17
Show member pathways
11.92 CCL11 CCL24 CCL26 IL13 IL15 IL18
18
Show member pathways
11.9 CCL11 CCL24 CCL26
19 11.81 IL3 IL4 IL5
20 11.78 IL13 IL15 IL18 IL33 IL4 IL5
21
Show member pathways
11.76 FOXP3 IL3 IL4 IL5
22 11.73 IL13 IL4 IL5
23 11.66 CCL11 CCL26 IL4 IL5
24 11.65 CCL11 IL13 IL4 IL5
25 11.49 IL13 IL18 IL4
26 11.46 CCL11 FOXP3 IL13 IL33 IL4 IL5
27 11.35 CCL11 CCL24 CCL26 IL13 IL15 IL18
28 11.29 IL13 IL15 IL3 IL4 IL5
29 11.2 IL13 IL4 IL5
30 11.14 IL13 IL15 IL18 IL33 IL4 IL5
31 11.11 IL13 IL18
32 10.92 CCL11 CCL24 CCL26 IL13 IL15 IL18
33 10.51 CCL11 CCL24 CCL26 IL13 IL15 IL18

GO Terms for Eosinophilic Gastritis

Cellular components related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL11 CCL24 CCL26 IL13 IL15 IL18
2 extracellular space GO:0005615 9.36 ATP4A CCL11 CCL24 CCL26 IL13 IL15

Biological processes related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 FOXP3 IL13 IL18 IL33 IL4
2 chemotaxis GO:0006935 9.84 CCL11 CCL24 CCL26
3 cellular response to tumor necrosis factor GO:0071356 9.83 CCL11 CCL24 CCL26
4 cellular response to interferon-gamma GO:0071346 9.8 CCL11 CCL24 CCL26
5 cell-cell signaling GO:0007267 9.8 CCL24 CCL26 IL15 IL18 IL3
6 cytokine-mediated signaling pathway GO:0019221 9.8 CCL11 IL13 IL18 IL3 IL4 IL5
7 inflammatory response GO:0006954 9.8 CCL11 CCL24 CCL26 IL13 IL15 IL18
8 positive regulation of cold-induced thermogenesis GO:0120162 9.79 IL13 IL18 IL4
9 neutrophil chemotaxis GO:0030593 9.79 CCL11 CCL24 CCL26
10 cellular response to interleukin-1 GO:0071347 9.77 CCL11 CCL24 CCL26
11 chemokine-mediated signaling pathway GO:0070098 9.77 CCL11 CCL24 CCL26
12 positive regulation of endothelial cell proliferation GO:0001938 9.76 CCL11 CCL24 CCL26
13 positive regulation of actin filament polymerization GO:0030838 9.72 CCL11 CCL24 CCL26
14 monocyte chemotaxis GO:0002548 9.69 CCL11 CCL24 CCL26
15 ATP hydrolysis coupled proton transport GO:0015991 9.67 ATP12A ATP4A
16 negative regulation of interferon-gamma production GO:0032689 9.67 FOXP3 IL33
17 positive regulation of inflammatory response GO:0050729 9.67 CCL24 IL15 IL18 IL33
18 positive regulation of interleukin-4 production GO:0032753 9.66 FOXP3 IL33
19 cellular sodium ion homeostasis GO:0006883 9.65 ATP12A ATP4A
20 positive regulation of macrophage activation GO:0043032 9.65 IL13 IL33
21 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.65 ATP12A ATP4A
22 positive regulation of B cell proliferation GO:0030890 9.65 IL13 IL4 IL5
23 cellular potassium ion homeostasis GO:0030007 9.64 ATP12A ATP4A
24 positive regulation of interleukin-17 production GO:0032740 9.64 IL15 IL18
25 sodium ion export across plasma membrane GO:0036376 9.63 ATP12A ATP4A
26 positive regulation of immunoglobulin secretion GO:0051024 9.63 IL33 IL5
27 lymphocyte chemotaxis GO:0048247 9.63 CCL11 CCL24 CCL26
28 positive regulation of interleukin-13 production GO:0032736 9.61 IL33 IL4
29 eosinophil chemotaxis GO:0048245 9.61 CCL11 CCL24 CCL26
30 immune response GO:0006955 9.61 CCL11 CCL24 CCL26 IL13 IL15 IL18
31 positive regulation of natural killer cell proliferation GO:0032819 9.58 IL15 IL18
32 positive regulation of neuroinflammatory response GO:0150078 9.57 IL18 IL33
33 positive regulation of tissue remodeling GO:0034105 9.56 IL15 IL18
34 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 IL13 IL15 IL18 IL3 IL4
35 type 2 immune response GO:0042092 9.54 IL18 IL4
36 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
37 regulation of signaling receptor activity GO:0010469 9.32 CCL11 CCL24 CCL26 IL13 IL15 IL18

Molecular functions related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.63 IL3 IL4 IL5
2 chemokine activity GO:0008009 9.58 CCL11 CCL24 CCL26
3 CCR chemokine receptor binding GO:0048020 9.5 CCL11 CCL24 CCL26
4 sodium:potassium-exchanging ATPase activity GO:0005391 9.43 ATP12A ATP4A
5 receptor ligand activity GO:0048018 9.43 CCL11 CCL24 CCL26
6 potassium:proton exchanging ATPase activity GO:0008900 9.37 ATP12A ATP4A
7 cytokine receptor binding GO:0005126 9.33 IL13 IL15 IL4
8 cytokine activity GO:0005125 9.32 CCL11 CCL24 CCL26 IL13 IL15 IL18
9 CCR3 chemokine receptor binding GO:0031728 9.13 CCL11 CCL24 CCL26

Sources for Eosinophilic Gastritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....